Indian Drug Makers Squeezed Between Bulk Costs, Price Controls
This article was originally published in PharmAsia News
Indian drug makers are facing an obstacle in getting drugs to market by the twin impact of increasing costs for raw materials and government pricing limits. Drug makers saw a 20 percent to 100 percent increase in the bulk drugs they imported from China during the past six months. At the same time, Indian pharmas face a 10 percent cap on their ability to raise prices. The conundrum could lead some companies to stop producing several drugs, in turn causing a shortage of those drugs on the market. Pharma industry estimates put the cost of raw materials at up to 60 percent of manufacturing costs. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.